Clinical trials: NPC
NPC, Locoregionally Advanced Nasopharyngeal Carcinoma
Pembrolizumab + MRGOO3 as Neoadjuvant in NPC
The goal of this clinical trial is to evaluate efficacy and safety of neoadjuvant of the anti PD1 agent Pembrolizumab combined with MRG003 and adjuvant treatment of Pembrolizumab in patients with Epstein-Barr virus (EBV) …
- Trial name
- NCT07267338
- Testing
- Pembrolizumab & MRG003
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Nasopharyngeal Cancinoma (NPC)
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
This phase III randomized, double-blind, placebo-controlled trial evaluates whether nanocrystalline megestrol acetate can reduce anorexia in patients with locally advanced nasopharyngeal carcinoma (NPC) undergoing concurrent…
- Trial name
- NCT07796789
- Testing
- Nanocrystalline Megestrol Acetate Oral Suspension
- Where
- 3 sites in China
- Volunteers
- 204 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
This Phase II study is a clinical trial exploring the efficacy and safety of BL-B01D1 with or without PD-1 monoclonal antibody in patients with high-risk locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07797881
- Testing
- BL-B01D1, PD-1 monoclonal antibody, Gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma (NPC)
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of PD-1 monoclonal antibody combined with chemotherapy, followed by maintenance therapy with PD-1…
- Trial name
- NCT07783321
- Testing
- BL-B01D1, PD-1 monoclonal antibody, cisplatin
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma (NPC), Myelosuppression
Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
This multicenter, prospective, observational cohort study aims to evaluate a previously developed dynamic risk prediction model for severe treatment-related myelosuppression in patients with nasopharyngeal carcinoma receiving…
- Trial name
- NCT07819656
- Where
- China
- Volunteers
- 1,782 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Carcinoma (NPC), Solid Tumors
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
This Phase Ib/II study is a clinical trial to evaluate the efficacy and safety of BL-M08D1 for Injection in patients with recurrent or metastatic nasopharyngeal carcinoma and other solid tumors.
- Trial name
- NCT07818486
- Testing
- BL-M08D1
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma (NPC)
Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: cfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection
This study focus on nasopharyngeal carcinoma, a cancer type with Chinese characteristics, analyze the early screening detection performance of nasopharyngeal carcinoma in the multi-cancer early screening model, and compare the…
- Trial name
- PROFOUND-NPC (NCT06763289)
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC)
Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
This single-center, Phase 1 study is evaluating the safety, tolerability, and preliminary antitumor activity of recombinant human endostatin adenovirus injection (EDS01) given by intratumoral injection in combination with…
- Trial name
- EDS01 HN (NCT07625423)
- Testing
- EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Nasopharyngeal Carcinoma (NPC), Screening
"Xijiang Project" Screening Cohort for NPC
The purpose of this study is to establish a comprehensive and integrated nasopharyngeal carcinoma screening cohort, which includes an epidemiological information database containing basic information, gender, age, ethnic and…
- Trial name
- NCT06787456
- Testing
- EBV antibodies test, EBV DNA test, epidemiological information survey
- Where
- China
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Ming-Yuan Chen
Nasopharyngeal Cancinoma (NPC)
Platinum-Free Regimen in Nasopharyngeal Carcinoma
This study aimed to investigate the efficacy of a platinum-free neoadjuvant regimen (gemcitabine, camrelizumab, endostar, and low-dose radiotherapy) followed by a risk-adapted therapeutic strategy in patients with locally…
- Trial name
- NCT07794488
- Testing
- Endostar (recombinant human endostatin injection)
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma (NPC), PET / CT
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
This is an observational cohort study designed to (1) evaluate whether Gallium-68 (68Ga)-labeled fibroblast activation protein inhibitor ligand LM3 (68Ga-FAPI-LM3) positron emission tomography/computed tomography (PET/CT)…
- Trial name
- NCT07137052
- Where
- China
- Volunteers
- 732 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Nasopharyngeal Cancinoma (NPC)
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
To evaluate the locoregional control, survival rate, toxicity, and quality of life in patients with nasopharyngeal carcinoma treated with reduced prophylactic irradiation doses to the Low-Risk Clinical Target Volume (CTV).
- Trial name
- NCT07201337
- Testing
- Radiation Therapy
- Where
- 6 sites in China
- Volunteers
- 700 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma
To evaluate whether the 2-year local failure-free survival (LRFFS) in Cohort 1 patients with AJCC/UICC 8th edition stage IB-II nasopharyngeal carcinoma who achieved EBV-DNA = 0 after induction chemotherapy and had MRI assessment…
- Trial name
- NCT07789158
- Testing
- reduced dose group, Standard Dose Group, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 269 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
This study plans to enroll patients with histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma. After signing informed consent, eligible subjects will receive three cycles of standard-dose becotatug…
- Trial name
- NCT07781358
- Testing
- Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hongmeng Yu
Nasopharyngeal Cancinoma (NPC)
Selective Neck Dissection Under Multimodal Assessment for N3 Nasopharyngeal Carcinoma After Radiotherapy
The goal of this phase I clinical trial is to evaluate the safety and feasibility of a multimodal evaluation-guided surveillance-intervention strategy in patients with newly diagnosed N3 nasopharyngeal carcinoma.
- Trial name
- NCT07636499
- Testing
- Multimodal Evaluation-Guided Surveillance-Intervention Strategy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guiquan Zhu
Nasopharyngeal Carcinoma (NPC), Osteoradionecrosis of the Jaw
Impacted Tooth Management and Osteoradionecrosis Risk in NPC
This multicenter, randomized controlled trial is designed to determine whether omitting prophylactic extraction of impacted teeth before radiotherapy leads to an unacceptably higher risk of jaw osteoradionecrosis (JORN) compared…
- Trial name
- NCT07764887
- Testing
- Omission of Prophylactic Impacted Tooth Extraction, Prophylactic Impacted Tooth Extraction
- Where
- 11 sites in China
- Volunteers
- 536 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma (NPC)
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
The main questions it aims to answer are: 1. Does the combination of GP induction chemotherapy and toripalimab improve the 3-year progression-free survival (PFS) compared to GP induction chemotherapy with placebo? 2.
- Trial name
- Navigation (NCT06712888)
- Testing
- TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy
- Where
- 10 sites in China
- Volunteers
- 466 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
This study aims to explore the efficacy and safety of risk-adapted adjuvant therapy based on dynamic EBV-DNA changes and MRI in nasopharyngeal carcinoma patients.
- Trial name
- NCT07762976
- Testing
- Observation, Adjuvant therapy
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
The RADIANCE trial plans to enroll patients with chemotherapy-ineligible de novo metastatic nasopharyngeal carcinoma (AJCC 9th edition, TxNxM1).
- Trial name
- RADIANCE (NCT07756190)
- Testing
- Sintilimab, ipilimumab, Radscopal Radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Biomarker Analysis Data From a Randomized Phase II Study in Patients With Nasopharyngeal Carcinoma Treated With Chemotherapy and Radiotherapy
Clinicopathological and genomic data (Next generation sequencing and IHC/CISH) in available tissues were performed in patients with nasopharyngeal carcinoma who participated in a previously conducted randomized phase II study…
- Trial name
- NCT07741110
- Testing
- Next generation sequencing, Immunohistochemistry/CISH
- Volunteers
- 141 people
- Sponsor
- Hellenic Cooperative Oncology Group